AstraZeneca plc 2.7% Potential Upside Indicated by Bryan Garnier

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc using EPIC/TICKER code (LON:AZN) has had its stock rating noted as ‘Retains’ with the recommendation being set at ‘BUY’ this morning by analysts at Bryan Garnier. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Bryan Garnier have set a target price of 8780 GBX on its stock. This indicates the analyst now believes there is a potential upside of 2.7% from today’s opening price of 8549 GBX. Over the last 30 and 90 trading days the company share price has increased 943 points and increased 784 points respectively. The 1 year high stock price is 8850 GBX while the year low share price is currently 5642 GBX.

AstraZeneca plc has a 50 day moving average of 7,581.17 GBX and a 200 Day Moving Average share price is recorded at 7,474.00. There are currently 1,312,241,922 shares in issue with the average daily volume traded being 2,685,316. Market capitalisation for LON:AZN is £111,855,501,431 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
    AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.

      Search

      Search